Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crossover study of umeclidinium, vilanterol, and umeclidinium + vilanterol in COPD
2011-005914-12Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium, vilanterol and Anoro Ellipta in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Weighted mean FEV1 over 0 to 6 hours post-dose on Day 14. Started Jun 2012; status: completed.
02
Drugs
umeclidiniumvilanterolAnoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-005914-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005914-12.